Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Sadif Analytics Prime
$25.00
Provider: Thomson Reuters StreetEvents
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Karolinska Development AB's Pergamum AB Reports Positive Follow-up Data from Phase II CLinical Trial of PXL-01 for Prevention of Post-Surgical Adhesions


Thursday, 27 Jun 2013 02:00am EDT 

Karolinska Development AB announced that Pergamum AB announced on June 27, 2013 that several end-points were met in a randomized Phase II trial of PXL-01 for prevention of post-surgical adhesions. Karolinska Development AB is the main owner of Pergamum. PXL-01 is a therapeutic peptide that has been developed with the purpose to reduce the formation of obstructing scars and restore mobility and function. Follow-up data from the Phase II clinical trial of PXL-01 at six and 12 months post-surgery revealed an improvement in functional hand recovery compared to placebo. Treatment was not associated with any safety issues or increase in the rate of tendon rupture. In total, 138 patients undergoing hand surgery were treated in this prospective, double-blind, randomized, placebo controlled clinical trial conducted in Sweden, Denmark and Germany. Top-line data from this study was first reported in July 2012.